Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 204

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 204
---
 and selling any common shares to the Selling Shareholders to the extent such shares, when aggregated with all other common shares then beneficially owned by the Selling Shareholder, would cause the Selling Shareholder's beneficial ownership of our common shares to exceed 4.99%. The SEPA also prohibits us from issuing or selling common shares under the SEPA in excess of the 19.99% Exchange Cap, unless we obtain shareholder approval to do so, or unless all applicable sales of common shares under the SEPA equal or exceed the "Minimum Price" (as such term is defined in Nasdaq Rule 5635).

<div align='center'>- 136 -</div>

(2)Assumes the sale of all common shares being offered pursuant to this prospectus.

(3)All investment decisions for the Selling Shareholder are made by Mr. Mark Angelo. The business address of the Selling Shareholder is 1012 Springfield Avenue, Mountainside, New Jersey 07092.

<div align='center'>- 137 -

PLAN OF DISTRIBUTION</div>

The common shares offered by this prospectus are being offered by the Selling Shareholder. The shares may be sold or distributed from time to time by the Selling Shareholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. We will not receive any of the proceeds from the sale of the securities by the Selling Shareholder. We may receive up to $15,000,000 aggregate gross proceeds under the SEPA from any sales we make to the Selling Shareholder pursuant to the SEPA. The net proceeds from sales, if any, under the SEPA, will depend on the frequency and prices at which we sell common shares to the Selling Shareholder after the date of this prospectus.

The sale of the common shares offered by this prospectus could be effected in one or more of the following methods:

ordinary brokers' transactions;

transactions involving cross or block trades;

through brokers, dealers, or underwriters who may act solely as agents;

"at the market" into an existing market for our common shares;

in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;

in privately negotiated transactions; or

any combination of the foregoing or any manner permitted under applicable law